This article delves into the importance and urgency of improving the quality of big data on dietary nutrition and chronic diseases within the disease control system. With the continuous rise in the incidence of chronic diseases, enhancing the quality of relevant data has become crucial in addressing public health challenges. The article proposes a series of concrete measures to improve the accuracy, completeness, and usability of the data, drawing on theoretical and technical support. By strengthening data collection, management, analysis, and application, the goal is to establish a high-quality big data system for dietary nutrition and chronic diseases. This will provide solid data support and scientific evidence for formulating targeted prevention and control strategies, supporting policy development, promoting scientific research innovation, and improving public health standards.

Objective:To understand the development status of maternal and child health care institutions in China from 2012 to 2022, identify the challenges they face, and provide references for further promoting the high-quality development of these institutions.Methods:Data from the China Health Statistics Yearbook (2013—2015), China Health and Family Planning Statistics Yearbook (2016—2017), and China Health and Wellness Statistics Yearbook (2018—2023) were used. Descriptive analysis was conducted on the data related to resource allocation and utilization efficiency, service provision, income and expenditure structure, and operational status of maternal and child health care institutions in China from 2012 to 2022, using methods such as fixed-base growth rate, year-on-year growth rate, and average annual growth rate. Results:From 2012 to 2022, the number of maternal and child health care institutions in China decreased from 3 044 to 3 031. In terms of resource allocation, the average annual growth rates of bed numbers and business-use floor area were 5.404% and 10.923%, respectively, while the average annual growth rate of health professionals was 7.183%. Regarding service provision, the average annual growth rates of outpatient visits and inpatient admissions were 3.954% and 1.572%, respectively. In terms of service efficiency, the bed occupancy rate decreased from 76.9% to 53.9%, and the average number of patients seen per physician per day decreased from 8.85 to 7.30. In terms of income and expenditure and operations, the income-expenditure surplus rate decreased from 9.16% to 5.41%, and the debt-to-asset ratio increased from 27.88% to 33.60%. During the same period, the average annual growth rates of bed numbers and business-use floor area in grassroots maternal and child health care institutions were 4.545% and 10.091%, respectively, lower than the national average. The number of outpatient visits increased from 89.03 million to 126.93 million, with an average annual growth rate of 3.610%, while the number of inpatient admissions decreased from 4.19 million to 3.91 million, with an average annual decline of 0.689%. The income-expenditure surplus rate of grassroots institutions decreased from 7.76% to 4.05%, 1.36 percentage points lower than the national level, and the debt-to-asset ratio increased from 27.53% to 36.37%, higher than the overall level.Conclusions:From 2012 to 2022, maternal and child health care institutions in China achieved certain developments in resource allocation and service scale. However, several challenges remain, including unbalanced resource allocation, decreased utilization efficiency, slowed growth in medical service volume, imbalanced income and expenditure structure, increased asset operation risks, and restricted development of grassroots institutions. It is recommended that relevant management departments and maternal and child health care institutions optimize resource allocation, plan for service transformation and upgrading, expand income sources, strengthen internal financial control, and reinforce the construction of high-quality and efficient maternal and child health care systems to promote the high-quality development of maternal and child health care institutions in China.

BACKGROUND:Currently,the treatment methods for colorectal cancer include surgical resection and chemotherapy.However,the subsequent quality of life of patients cannot be improved due to the multiple surgical complications and drug resistance in the later stage of chemotherapy.OBJECTIVE:To review the mechanism of action,latest progress and existing problems of exosomes derived from mesenchymal stem cells in the treatment of colorectal cancer.METHODS:PubMed,CNKI and WanFang databases were searched for relevant literature using the search terms of"mesenchymal stem cells exosomes,colorectal cancer,chemotherapy,treatment"in Chinese and English,respectively.Finally,96 articles were included for analysis.RESULTS AND CONCLUSION:(1)Mesenchymal stem cell-derived exosomes play different roles in the treatment of colorectal cancer mainly through the microRNAs and long-chain non-coding RNAs carried by themselves to mediate different signaling pathways.(2)Mesenchymal stem cell-derived exosomes are highly stable and biocompatible,which makes them excellent carriers of therapeutic drugs.(3)Mesenchymal stem cell-derived exosomes have different effects on resistance to different types of chemotherapeutic agents.

BACKGROUND:Early treatment methods for colorectal cancer include endoscopy and surgical resection,but there are many postoperative complications.Chemotherapy is the most common treatment for late-stage colorectal cancer,but chemotherapy can cause gastrointestinal dysfunction,bone marrow suppression,liver and kidney function damage,and other adverse reactions.As a result,most patients are not proactive and do not cooperate with treatment.OBJECTIVE:To review the mechanism of action,latest treatment progress,and current problems of mesenchymal stem cells in the treatment of colorectal cancer,and provide a basis for future clinical application.METHODS:PubMed,CNKI,and WanFang databases were searched for relevant literature using the keywords of"mesenchymal stem cells,colorectal cancer,cancer stem cell,tumor microenvironment"in Chinese and English,respectively.Finally,119 articles were included for analysis.RESULTS AND CONCLUSION:(1)Mesenchymal stem cells have both promoting and inhibiting effects on colorectal cancer.(2)The tumor homing characteristics of mesenchymal stem cells enable them to migrate accurately to the tumor site and release drugs,which increases the safety and effectiveness of the treatment of colorectal cancer.(3)Exosomes derived from mesenchymal stem cells can serve as good carriers and shows a good application prospect in the targeted therapy of colorectal cancer.(4)Using viral vectors,non-viral vectors,or other transfection tools,drugs with mature anti-tumor effects can be loaded into mesenchymal stem cells for the treatment of colorectal cancer.(5)The combined use of mesenchymal stem cells and chemotherapy drugs can improve the efficacy of chemotherapy drugs and reduce the adverse reactions of chemotherapy drugs.(6)The mechanism by which mesenchymal stem cells promote the development of colorectal cancer is mainly related to the expression status of signal transduction and chemotactic factors in colorectal cancer cells and the transformation of mesenchymal stem cells into cancer-related fibroblasts.(7)Mesenchymal stem cells may have the characteristics of driving cancer stem cells,promoting tumor initiation and increasing tumor invasion.(8)There are still some unavoidable problems in the treatment of colorectal cancer with mesenchymal stem cells:lack of standardized treatment plans and efficacy evaluation,high treatment costs,preservation and transportation of mesenchymal stem cells,and the proportion of combined use of mesenchymal stem cells and chemotherapy drugs.

This article delves into the importance and urgency of improving the quality of big data on dietary nutrition and chronic diseases within the disease control system. With the continuous rise in the incidence of chronic diseases, enhancing the quality of relevant data has become crucial in addressing public health challenges. The article proposes a series of concrete measures to improve the accuracy, completeness, and usability of the data, drawing on theoretical and technical support. By strengthening data collection, management, analysis, and application, the goal is to establish a high-quality big data system for dietary nutrition and chronic diseases. This will provide solid data support and scientific evidence for formulating targeted prevention and control strategies, supporting policy development, promoting scientific research innovation, and improving public health standards.

BACKGROUND:Currently,the treatment methods for colorectal cancer include surgical resection and chemotherapy.However,the subsequent quality of life of patients cannot be improved due to the multiple surgical complications and drug resistance in the later stage of chemotherapy.OBJECTIVE:To review the mechanism of action,latest progress and existing problems of exosomes derived from mesenchymal stem cells in the treatment of colorectal cancer.METHODS:PubMed,CNKI and WanFang databases were searched for relevant literature using the search terms of"mesenchymal stem cells exosomes,colorectal cancer,chemotherapy,treatment"in Chinese and English,respectively.Finally,96 articles were included for analysis.RESULTS AND CONCLUSION:(1)Mesenchymal stem cell-derived exosomes play different roles in the treatment of colorectal cancer mainly through the microRNAs and long-chain non-coding RNAs carried by themselves to mediate different signaling pathways.(2)Mesenchymal stem cell-derived exosomes are highly stable and biocompatible,which makes them excellent carriers of therapeutic drugs.(3)Mesenchymal stem cell-derived exosomes have different effects on resistance to different types of chemotherapeutic agents.

BACKGROUND:Early treatment methods for colorectal cancer include endoscopy and surgical resection,but there are many postoperative complications.Chemotherapy is the most common treatment for late-stage colorectal cancer,but chemotherapy can cause gastrointestinal dysfunction,bone marrow suppression,liver and kidney function damage,and other adverse reactions.As a result,most patients are not proactive and do not cooperate with treatment.OBJECTIVE:To review the mechanism of action,latest treatment progress,and current problems of mesenchymal stem cells in the treatment of colorectal cancer,and provide a basis for future clinical application.METHODS:PubMed,CNKI,and WanFang databases were searched for relevant literature using the keywords of"mesenchymal stem cells,colorectal cancer,cancer stem cell,tumor microenvironment"in Chinese and English,respectively.Finally,119 articles were included for analysis.RESULTS AND CONCLUSION:(1)Mesenchymal stem cells have both promoting and inhibiting effects on colorectal cancer.(2)The tumor homing characteristics of mesenchymal stem cells enable them to migrate accurately to the tumor site and release drugs,which increases the safety and effectiveness of the treatment of colorectal cancer.(3)Exosomes derived from mesenchymal stem cells can serve as good carriers and shows a good application prospect in the targeted therapy of colorectal cancer.(4)Using viral vectors,non-viral vectors,or other transfection tools,drugs with mature anti-tumor effects can be loaded into mesenchymal stem cells for the treatment of colorectal cancer.(5)The combined use of mesenchymal stem cells and chemotherapy drugs can improve the efficacy of chemotherapy drugs and reduce the adverse reactions of chemotherapy drugs.(6)The mechanism by which mesenchymal stem cells promote the development of colorectal cancer is mainly related to the expression status of signal transduction and chemotactic factors in colorectal cancer cells and the transformation of mesenchymal stem cells into cancer-related fibroblasts.(7)Mesenchymal stem cells may have the characteristics of driving cancer stem cells,promoting tumor initiation and increasing tumor invasion.(8)There are still some unavoidable problems in the treatment of colorectal cancer with mesenchymal stem cells:lack of standardized treatment plans and efficacy evaluation,high treatment costs,preservation and transportation of mesenchymal stem cells,and the proportion of combined use of mesenchymal stem cells and chemotherapy drugs.

Objective:To understand the development status of maternal and child health care institutions in China from 2012 to 2022, identify the challenges they face, and provide references for further promoting the high-quality development of these institutions.Methods:Data from the China Health Statistics Yearbook (2013—2015), China Health and Family Planning Statistics Yearbook (2016—2017), and China Health and Wellness Statistics Yearbook (2018—2023) were used. Descriptive analysis was conducted on the data related to resource allocation and utilization efficiency, service provision, income and expenditure structure, and operational status of maternal and child health care institutions in China from 2012 to 2022, using methods such as fixed-base growth rate, year-on-year growth rate, and average annual growth rate. Results:From 2012 to 2022, the number of maternal and child health care institutions in China decreased from 3 044 to 3 031. In terms of resource allocation, the average annual growth rates of bed numbers and business-use floor area were 5.404% and 10.923%, respectively, while the average annual growth rate of health professionals was 7.183%. Regarding service provision, the average annual growth rates of outpatient visits and inpatient admissions were 3.954% and 1.572%, respectively. In terms of service efficiency, the bed occupancy rate decreased from 76.9% to 53.9%, and the average number of patients seen per physician per day decreased from 8.85 to 7.30. In terms of income and expenditure and operations, the income-expenditure surplus rate decreased from 9.16% to 5.41%, and the debt-to-asset ratio increased from 27.88% to 33.60%. During the same period, the average annual growth rates of bed numbers and business-use floor area in grassroots maternal and child health care institutions were 4.545% and 10.091%, respectively, lower than the national average. The number of outpatient visits increased from 89.03 million to 126.93 million, with an average annual growth rate of 3.610%, while the number of inpatient admissions decreased from 4.19 million to 3.91 million, with an average annual decline of 0.689%. The income-expenditure surplus rate of grassroots institutions decreased from 7.76% to 4.05%, 1.36 percentage points lower than the national level, and the debt-to-asset ratio increased from 27.53% to 36.37%, higher than the overall level.Conclusions:From 2012 to 2022, maternal and child health care institutions in China achieved certain developments in resource allocation and service scale. However, several challenges remain, including unbalanced resource allocation, decreased utilization efficiency, slowed growth in medical service volume, imbalanced income and expenditure structure, increased asset operation risks, and restricted development of grassroots institutions. It is recommended that relevant management departments and maternal and child health care institutions optimize resource allocation, plan for service transformation and upgrading, expand income sources, strengthen internal financial control, and reinforce the construction of high-quality and efficient maternal and child health care systems to promote the high-quality development of maternal and child health care institutions in China.

Evidence indicates that metabolic reprogramming characterized by the changes in cellular metabolic patterns contributes to the pathogenesis of pulmonary fibrosis(PF).It is considered as a promising ther-apeutic target anti-PF.The well-documented against PF properties of Tanshinone ⅡA(Tan ⅡA)have been primarily attributed to its antioxidant and anti-inflammatory potency.Emerging evidence suggests that TanⅡA may target energy metabolism pathways,including glycolysis and tricarboxylic acid(TCA)cycle.However,the detailed and advanced mechanisms underlying the anti-PF activities remain obscure.In this study,we applied[U-13C]-glucose metabolic flux analysis(MFA)to examine metabolism flux disruption and modulation nodes of Tan ⅡA in PF.We identified that Tan ⅡA inhibited the glycolysis and TCA flux,thereby suppressing the production of transforming growth factor-β1(TGF-β1)-dependent extracellular matrix and the differentiation and proliferation of myofibroblasts in vitro.We further revealed that Tan ⅡA inhibited the expression of key metabolic enzyme hexokinase 2(HK2)by inhibiting phosphoinositide 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin(mTOR)/hypoxia-inducible factor 1α(HIF-1α)pathway activities,which decreased the accumulation of abnormal metabolites.Notably,we demonstrated that Tan ⅡA inhibited ATP citrate lyase(ACLY)activity,which reduced the collagen synthesis pathway caused by cytosol citrate consumption.Further,these results were validated in a mouse model of bleomycin-induced PF.This study was novel in exploring the mechanism of the occurrence and develop-ment of Tan ⅡA in treating PF using 13C-MFA technology.It provided a novel understanding of the mechanism of Tan ⅡA against PF from the perspective of metabolic reprogramming.

Objective:To analyze the allocation of general practitioners per 10 000 population in China and its influencing factors, so as to provide reference for optimizing the allocation of general practitioners resources in China.Methods:The number of general practitioners per 10 000 population and other relevant data of 31 provinces (except Hong Kong, Macao and Taiwan) in China from 2012 to 2021 were collected from China Statistical Yearbook, China Health Statistics Yearbook, China Health and Family Planning Statistical Yearbook. The geographical area data of 31 provinces (except Hong Kong, Macao and Taiwan) from 2012 to 2021 were retrieved from the website of the Central People ′s Government. The influencing factors of the number of general practitioners per 10 000 population were preset by literature analysis and unstructured interview. Taking the number of general practitioners per 10 000 population as the dependent variable, the correlation between it and the preset influencing factors was analyzed by panel data regression. Results:From 2012 to 2021, the average annual growth rate of the number of general practitioners per 10 000 population in each province of China was greater than 0. The factors affecting the number of general practitioners per 10 000 population included the number of people per square kilometer ( r=3.818, P<0.01), the number of beds in medical and health institutions per capita ( r=2.135, P<0.01), the proportion of the elderly population aged 65 and above ( r=0.180, P<0.01), and the proportion of total expenditure in medical and health institutions to gross domestic product ( r=0.080, P<0.01). Conclusions:The development trend of general practitioners resources allocation in China is good, but the government needs to integrate the population agglomeration and aging trend, the allocation of medical and health resources, the investment support for the development of general practitioners and other influencing factors, optimize the allocation of general practitioners resources according to local conditions, and strengthen policy support for areas and links where the allocation of general practitioners resources is relatively weak.